- Home
- TKO vs LEGN Comparison
TKO vs LEGN Comparison
Compare TKO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKO
- LEGN
- Stock Information
- Founded
- TKO 1980
- LEGN 2014
- Country
- TKO United States
- LEGN United States
- Employees
- TKO N/A
- LEGN N/A
- Industry
- TKO
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- TKO
- LEGN Health Care
- Exchange
- TKO Nasdaq
- LEGN Nasdaq
- Market Cap
- TKO 15.6B
- LEGN 6.7B
- IPO Year
- TKO N/A
- LEGN 2020
- Fundamental
- Price
- TKO $204.49
- LEGN $33.88
- Analyst Decision
- TKO Strong Buy
- LEGN Strong Buy
- Analyst Count
- TKO 14
- LEGN 12
- Target Price
- TKO $193.58
- LEGN $73.36
- AVG Volume (30 Days)
- TKO 736.8K
- LEGN 1.1M
- Earning Date
- TKO 11-05-2025
- LEGN 11-11-2025
- Dividend Yield
- TKO 0.75%
- LEGN N/A
- EPS Growth
- TKO N/A
- LEGN N/A
- EPS
- TKO 1.78
- LEGN N/A
- Revenue
- TKO $2,965,944,000.00
- LEGN $796,838,000.00
- Revenue This Year
- TKO $68.81
- LEGN $70.75
- Revenue Next Year
- TKO $26.28
- LEGN $52.47
- P/E Ratio
- TKO $113.58
- LEGN N/A
- Revenue Growth
- TKO N/A
- LEGN 74.75
- 52 Week Low
- TKO $114.01
- LEGN $27.34
- 52 Week High
- TKO $212.49
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- TKO 70.19
- LEGN 41.24
- Support Level
- TKO $192.84
- LEGN $32.70
- Resistance Level
- TKO $200.71
- LEGN $34.71
- Average True Range (ATR)
- TKO 5.20
- LEGN 1.18
- MACD
- TKO 1.06
- LEGN -0.06
- Stochastic Oscillator
- TKO 74.26
- LEGN 31.31
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.